Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

GameStop Corp GME

GameStop Corp. offers games and entertainment products through its stores and e-commerce platforms. The Company operates in four geographic segments: United States, Canada, Australia and Europe. Each segment consists primarily of retail operations, with the significant majority focused on games, entertainment products and technology. The Company has a total of approximately 4,169 stores across all of its segments: 2,915 in the United States, 203 in Canada, 404 in Australia, and 647 in Europe. Its stores and e-commerce sites operate primarily under the names GameStop, EB Games and Micromania. Its Australia and Europe segments also include approximately 49 pop culture themed stores selling collectibles, apparel, gadgets, electronics, toys and other retail products for technology enthusiasts and general consumers in international markets operating under the Zing Pop Culture brand. The Company's brands also include its print and digital gaming publication, Game Informer magazine.


NYSE:GME - Post by User

Post by DianaScanlanon Jun 03, 2022 5:23am
110 Views
Post# 34728770

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance




FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>